Package Leaflet: Information for the User
Levobupivacaine Kabi 1.25 mg/ml solution for infusion EFG
Levobupivacaine hydrochloride
Read all of this leaflet carefully before you start using this medicine,because it contains important information for you.
Contents of the pack:
Levobupivacaine Kabi belongs to a group of medicines called local anesthetics. This type of medicine is used to numb parts of the body or to relieve pain.
Levobupivacaine Kabi solution for infusion is only for use in adults.
Levobupivacaine Kabi is used to treat pain :
Do not use Levobupivacaine Kabi:
Warnings and precautions
Tell your doctor before you are given Levobupivacaine Kabi if you have any of the following conditions or diseases. You may need closer monitoring or a lower dose.
Children
Do not give this medicine to children because the safety and efficacy of this medicine for the treatment of pain in children have not been established.
Using Levobupivacaine Kabi with other medicines
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. Tell them especially if you are taking medicines for:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Levobupivacaine Kabi should not be given to relieve pain by injecting it into the area around the uterine cervix during childbirth (paracervical block).
The effects of Levobupivacaine Kabi on the fetus during the first stages of pregnancy are not known. Therefore, Levobupivacaine Kabi should not be used during the first three months of pregnancy, unless your doctor considers it necessary.
It is not known whether levobupivacaine passes into breast milk. However, based on experience with similar drugs, it is expected that only small amounts of levobupivacaine will pass into breast milk. Breastfeeding is therefore possible after using a local anesthetic.
Driving and using machines
The use of Levobupivacaine Kabi may have a considerable effect on your ability to drive and use machines. Do not drive or use machinery until the effects of Levobupivacaine Kabi and the effects of the surgery have worn off. Before you leave the hospital, ask your doctor or nurse if you can drive or use machines.
Levobupivacaine Kabi contains sodium
This medicine contains 3.6 mg of sodium (main component of cooking/table salt) per ml. This is equivalent to 0.18% of the maximum recommended daily intake of sodium for an adult.
Your doctor will give you Levobupivacaine Kabi through a small tube inserted into your back (epidural). Your doctor and nurse will carefully monitor you while you are being given Levobupivacaine Kabi.
Dose
Adults:
The amount of Levobupivacaine Kabi that will be given to you and how often it will be given will depend on what it is used for and your physical condition, age, and weight. You will be given the minimum dose that achieves anesthesia in the required area. The dose will be carefully calculated by your doctor.
When Levobupivacaine Kabi is used to relieve pain during childbirth, the dose given will be carefully controlled.
Children:
Not recommended.
If you are given too much Levobupivacaine Kabi
If you are given too much Levobupivacaine Kabi, you may experience numbness of the tongue, dizziness, blurred vision, muscle contraction, severe difficulty breathing (including respiratory arrest) and even convulsions. If you notice any of these symptoms, tell your doctor immediately. In some cases, the administration of an excessive amount of Levobupivacaine Kabi may also cause low blood pressure, bradycardia or tachycardia and changes in your heart rhythm. Your doctor may give you other medicines to help stop these symptoms.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse immediately if you think you are experiencing any of the following side effects.Some of the side effects of Levobupivacaine Kabi can be serious.
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Frequency not known(frequency cannot be estimated from the available data):
Bradyarrhythmia, tachyarrhythmia, and changes in heart rhythm that can be seen on an electrocardiogram (ECG) have also been reported as side effects.
In very rare cases, some side effects may occur after long-term use or may become permanent.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency's Pharmacovigilance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date is the last day of the month shown.
Your doctor will store this medicine for you.
The solution should be used immediately after opening.
Do not use this medicine if you notice particles in the solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Levobupivacaine Kabi
Levobupivacaine Kabi 1.25 mg/ml solution for infusion:
1 ml of solution contains 1.25 mg of levobupivacaine (as hydrochloride).
Each 100 ml bag contains 125 mg of levobupivacaine as levobupivacaine hydrochloride.
Each 200 ml bag contains 250 mg of levobupivacaine as levobupivacaine hydrochloride.
This medicine contains a known excipient with a potential effect (sodium). See section 2 for further information.
pH: 4.0 – 6.0
Osmolality: 271 – 332 mOsmol/l
Appearance and packaging
This medicine is a clear, colorless solution in a polyolefin bag with a transparent overwrap. It is supplied in packs of 5, 24, or 60 bags of 100 ml or 5, 12, or 32 bags of 200 ml of solution.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Fresenius Kabi España S.A.U
C/ Marina 16-18, 17th floor
08005-BARCELONA
Manufacturer:
HP Halden Pharma AS
Svinesundsveien 80
1788 Halden
Norway
This medicine is authorized in the Member States of the European Economic Area under the following names:
Levobupivacaine Kabi 1.25 mg/ml solution for infusion
Member State | Marketing authorization name |
Belgium | Levobupivacaïne Fresenius Kabi 1.25 mg/ml oplossing voor infusie |
France | Levobupivacaïne Kabi 1,25 mg/ml, solution pour perfusion |
Ireland | Levobupivacaine 1.25 mg/ml solution for infusion |
Italy | Levobupivacaina Kabi |
Netherlands | Levobupivacaïne Fresenius Kabi 1.25 mg/ml oplossing voor infusie |
Slovenia | Levobupivakain Kabi 1,25 mg/ml raztopina za infundiranje |
Spain | Levobupivacaina Kabi 1,25 mg/ml solución para perfusión |
United Kingdom | Levobupivacaine 1.25 mg/ml solution for infusion |
Date of last revision of this leaflet: October 2018
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/
-------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Levobupivacaine Kabi1.25 mg/ml solution for infusion EFG
Instructions for use / handling
Levobupivacaine Kabi 1.25 mg/ml solution for infusion is for single use only and should be administered via the epidural route and not intravenously. Use only if the solution is clear and the packaging is intact. Discard any unused solution.
As with all parenteral medicines, the solution/dilution should be inspected visually before use. Only clear solutions without visible particles should be used.
Validity period after dilution:
The chemical and physical stability of levobupivacaine solution for infusion has been demonstrated
From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions before use are the responsibility of the user and normally should not exceed 24 hours at 2-8º C, unless the mixture has been prepared in controlled and validated aseptic conditions.
Levobupivacaine Kabi should not be mixed with other medicines except those mentioned above. Dissolution with alkaline solutions such as sodium bicarbonate may cause precipitation.
Experience with the safety of levobupivacaine treatment for more than 24 hours is limited.
Method of administration
Administration of Levobupivacaine Kabi should only be performed by a doctor who has the necessary training and experience or under their supervision.
For information on dosage, refer to the Summary of Product Characteristics.
Careful aspiration should be performed before injection to prevent intravascular injection. If toxic symptoms appear, the injection should be stopped immediately.